UnitedHealth Group (UNH) Q3 2026 Earnings Call: Q&A Summary

Q: Justin Lake from Wolfe Research asked about Medicaid run rates, drivers of improvement, breakeven status, and current Medicare Advantage margins.

A: Michael Cotton stated that Medicaid membership and performance were within expectations, expecting full year 2026 performance moderately better than the forecasted range due to complex care cost management, network curation, and fraud removal, with an aspiration to reach rated margins by the end of 2028. Bobby added that Medicare Advantage margins are expected to be near the top end of the 2% to 4% range.

Q: Lance Wilkes from Bernstein asked about approaching 2027 growth in Medicare Advantage, national accounts, and the PBM selling season.

A: Bobby noted that Medicare Advantage features an expanded footprint with over 94% access, focusing on DSNP, CSNP, and HMO offerings. Brandon Davis stated that national accounts and mid-market selling seasons are very strong with high group retention. Jon Mahrt added that PBM client retention is in the high 90s with external membership north of 50%.

Q: Stephen Baxter from Wells Fargo asked about top line dynamics and repositioning for growth in Optum Health and Optum Insight.

A: Krista Nelson highlighted strong clinical programs and medical management, noting 20 million patients today with 4 million in fully accountable relationships and expanding service lines. Sandeep Dadlani explained that Optum Insight is investing in AI-first products, noting tools like Optum Integrity One growing from 2 clients at the end of 2025 to 15 implemented clients.

Q: A.J. Rice from UBS asked about commercial business margins, cost pressures, and the pacing of recovery.

A: Timothy Noel stated that commercial medical cost trends are stabilizing but remain elevated above historical norms, noting that utilization pressures will stretch out the timeline to achieve long-term margin objectives.

Q: Ann Hynes from Mizuho Securities asked about MA competitiveness regarding benefit offerings and potential for membership growth next year.

A: Bobby emphasized a deliberate approach for 2027 focusing on product stability and investments in DSNP, CSNP, and high-value HMO plans to capture growth opportunities.

Q: Kevin Fischbeck from Bank of America asked if trend acceleration in the back half of the year is consistent with company observations and how well 2027 is repriced.

A: Timothy Noel clarified that they are not seeing trend acceleration, noting commercial stabilization above 11%, Medicaid moderation, and better-than-expected Medicare performance, with all latest data incorporated into forward pricing.

Q: Scott Fidel from Goldman Sachs asked how cyclical margin recovery and OB3 reform implementation will interact for Medicaid margins through 2030.

A: Michael Cotton stated that they expect to return to rated margins in 2028 through clinical care management and AI tools, viewing Medicaid as a good, durable, and growing marketplace long term.

Q: Lisa Gill from JPMorgan asked about specialty pharmacy infusion capabilities, biosimilar opportunities, and how external PBM clients integrate medical and pharmacy.

A: Patrick Conway and Jon Mahrt noted that specialty volume grew 2.6% for the quarter with strong LDD win rates and 15 centers of excellence, infusion is expanding as a lower-cost setting, biosimilars show robust uptake, and services integrate seamlessly with PBM clients.

Q: Erin Wright from Morgan Stanley asked how to think about Optum Health margins for 2027 relative to the 6% to 8% target and potential structural constraints.

A: Krista Nelson stated that 2027 will be a year of strong pacing toward the 6% to 8% target by 2028, supported by ongoing core performance improvements and multiple growth domains.

Q: Andrew Mok from Barclays asked about Optum Health fourth quarter seasonality and quantifying investments impacting the segment.

A: Krista Nelson explained that fourth quarter EBIT reflects normal risk seasonality and additional investments in technology, AI, and clinician workflows to support expanded access and long-term performance.

Q: Matthew Gillmor from KeyBanc asked how quality programs and IDR dispute resolution processes should evolve constructively over the next few years.

A: Timothy Noel stated that while they support the spirit of the No Surprises Act, current IDR dispute resolution awards are excessive and hurt affordability. Bobby added that they support thoughtful MA modernization in collaboration with CMS and broad stakeholders.

Q: Ryan Langston from TD Cowen asked about the size and type of investments in the Stars program and the broker strategy for open enrollment.

A: Bobby stated that they improved nearly every clinical and Rx measure year-over-year in Stars and are accelerating investments in Q4 and 2027, while aligning broker and marketing strategies dynamically toward DSNP, CSNP, and HMO growth areas.